Vinny Pizzuti

Chief Medical Resident ‘26-‘27 @CUDeptMedicine via @WVUMedSchool, @NDCBE and @PurdueChemE | Future heme/onc hopeful | he/him | Views my own

[Vinny Pizzuti @vpizzuti44]

Grateful to @majorajay and all of our colleagues for the support of this work, and excited to share these findings!

[Ajay Major, MD, MBA @majorajay]

A huge congratulations to my mentee Dr. @vpizzuti44 on this analysis of two years of PRO data in CAR-T recipients, now published @BloodPortfolio.
CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent treatment response as a "PRO-marker."
More work to be done to investigate how PRO tools can be used in clinical decision-making. #lymsm #mmsm
https://t.co/idoksgFj7A

[CU Anschutz Lymphoma Program @CULymphoma]

Chief resident Dr. @vpizzuti44 @CUDeptMedicine and @CUHematology faculty Dr. @majorajay just published an analysis of longitudinal patient-reported outcomes over two years after receipt of CAR T-cell therapy, now in @BloodPortfolio. #lymsm #mmsm
https://t.co/4alwM1kz9O

[eJHaem Journal @e_JHaem]

Weekly Cladribine Followed by Rituximab for the Treatment of Hairy Cell Leukemia
https://t.co/QTvfj3APsb

[Vinny Pizzuti @vpizzuti44]

@MedicineCU @cu_medicine @CUMedicalSchool @CULymphoma

Grateful to @ASH_hematology, @mana1981, my program, and all my mentors for supporting this research!

[Vinny Pizzuti @vpizzuti44]

Excited to present a poster detailing my work under the guidance of @mana1981 developing a PET/CT radiomics model that may outperform standard prognostic scores in TP53-aberrant DLBCL on 6/1/26 @ASCO!

https://t.co/pkU5P7IgCO

[Vinny Pizzuti @vpizzuti44]

I am happy to announce I was selected by @ASH_Hematology to receive the ASH HONORS Award!

Excited for this project studying PET/CT radiomics in DLBCL. Grateful to @mana1981 for her mentorship and ASH for the support!
#ASHAwards #Fight4Hematology
@CULymphoma @CUDeptMedicine

[Vinny Pizzuti @vpizzuti44]

@CULymphoma @CUDeptMedicine

[Vinny Pizzuti @vpizzuti44]

Interested in patient reported outcomes (PROs) in patients with lymphoma? Join me as I recap my poster highlighting our work on the BISON PRO QoL Study presented at #ASH24 #lymsm

[Vinny Pizzuti @vpizzuti44]

Be on the lookout for a manuscript next year further describing our work! Big thanks to @ASH_hematology for allowing me to present and my mentor @majorajay for all the guidance and support!

Check out for more info:
- https://t.co/itwci8eokY
- https://t.co/nAgyyFisb4

[Vinny Pizzuti @vpizzuti44]

Really grateful to have had the opportunity to present a poster highlighting my work with @majorajay at #ASH2024 it was a great experience with a great group of people!

[Ajay Major, MD, MBA @majorajay]

Sneak peek of my mentee @vpizzuti44's heatmap analysis of longitudinal PROs from our @CUHematology BISON-PRO Quality of Life Study (https://t.co/BhuYULILsE). His abstract is at tonight's #ASH24 poster session; big congrats on an ASH Achievement Award for his work! #MajorPROsASH

[Vinny Pizzuti @vpizzuti44]

Really excited for my first ASH! #ASH2024